Novel Nanosized Gd3+-ALGD-G2-C595: In vivo Dual Selective MUC-1 Positive Tumor Molecular MR Imaging and Therapeutic Agent
- *Corresponding Author:
- Mehdi Mirzaei, MD
Department of Medical Physics and Biomedical Engineering
School of Medicine
Shahid Beheshti University of Medical Sciences
E-mail: dr_ [email protected]
Received Date: July 28, 2012; Accepted Date: September 11, 2012; Published Date: September 13, 2012
Citation: Mirzaei M, Mohagheghi M, Shahbazi-Gahrouei D, Khatami A (2012) Novel Nanosized Gd3+-ALGD-G2-C595: In vivo Dual Selective MUC-1 Positive Tumor Molecular MR Imaging and Therapeutic Agent. J Nanomed Nanotechol 3:147. doi:10.4172/2157-7439.1000147
Copyright: © 2012 Mirzaei M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Scope of this study is to synthesize a nano-dendrimer and its conjugate with C595 MAb against breast cancer cell, followed by its chelating agent with Gd3+. At the end, its use as a dual nanosized probe for detection and treatment was investigated. Anti-MUC-1 MAb C595 was coupled to a biodegradable biocompatible anionic linear globular dendrimer, ALGDG2, Poly ethylene glycol PEG core and citric acid shell followed by loading with Gd3+ to make novel MR imaging contrast agents. Anticancer effects and MR imaging parameters of the prepared nanoconjugate was investigated in vitro: cell toxicity, apoptosis and TNF-alpha, hemolysis, LDH evaluations as well as toxicity, biodistribution and MR imaging of cancer place were investigated. Results showed good tumor accumulation and detection, no in vivo toxicity, and potential selective anti-breast cancer activity. In conclusion, findings of this study showed that Gd3+-ALGDG2-C595 nano-probe is potentially both, a selective breast molecular imaging tool as well as a therapeutic agent. Further, subsequent clinical trials appear warranted.